Skip to main content
Explore URMC



Deborah A. Mulford, M.D.



Showing all 17 journal articles & 1 books available

Journal Articles

Gajra A, Ali H, Amiri KI, Karim NA, Matrana MR, Mulford D, Ong TJ, Sanford A, Santos ES, Socinski MA, Spigel DR. "PS01.08: ABOUND.PS2 Interim Safety Results: nab-Paclitaxel/Carboplatin Followed by nab-Paclitaxel in NSCLC Patients with ECOG PS of 2: Topic: Medical Oncology." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.. 2016 Nov 0; 11(11S):S274. Epub 2016 Oct 28.

Advani AS, McDonough S, Copelan E, Willman C, Mulford DA, List AF, Sekeres MA, Othus M, Appelbaum FR. "SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia." British journal of haematology.. 2014 Oct 0; 167(2):233-7. Epub 2014 Jul 18.

Liesveld JL, O'Dwyer K, Walker A, Becker MW, Ifthikharuddin JJ, Mulford D, Chen R, Bechelli J, Rosell K, Minhajuddin M, Jordan CT, Phillips GL. "A phase I study of decitabine and rapamycin in relapsed/refractory AML." Leukemia research.. 2013 Dec 0; 37(12):1622-7. Epub 2013 Sep 08.

Raza A, Galili N, Mulford D, Smith SE, Brown GL, Steensma DP, Lyons RM, Boccia R, Sekeres MA, Garcia-Manero G, Mesa RA. "Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)." Journal of hematology & oncology. 2012 Apr 30; 5:18. Epub 2012 Apr 30.

Raza A, Galili N, Smith SE, Godwin J, Boccia RV, Myint H, Mahadevan D, Mulford D, Rarick M, Brown GL, Schaar D, Faderl S, Komrokji RS, List AF, Sekeres M. "A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome." Cancer.. 2012 Apr 15; 118(8):2138-47. Epub 2011 Sep 01.

Liesveld JL, Rosell KE, Bechelli J, Lu C, Messina P, Mulford D, Ifthikharuddin JJ, Jordan CT, Phillips Ii GL. "Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines." Cancer investigation.. 2011 Aug 0; 29(7):439-50.

Sekeres MA, Gundacker H, Lancet J, Advani A, Petersdorf S, Liesveld J, Mulford D, Norwood T, Willman CL, Appelbaum FR, List AF. "A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605." Blood.. 2011 Jul 21; 118(3):523-8. Epub 2011 May 06.

Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, Heaney ML, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG. "Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia." Clinical cancer research : an official journal of the American Association for Cancer Research.. 2010 Nov 1; 16(21):5303-11. Epub 2010 Sep 21.

Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C. "Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML." Leukemia research.. 2008 Dec 0; 32(12):1830-6. Epub 2008 Jun 20.

Laughlin TS, Becker MW, Liesveld JL, Mulford DA, Abboud CN, Brown P, Rothberg PG. "Rapid method for detection of mutations in the nucleophosmin gene in acute myeloid leukemia." The Journal of molecular diagnostics : JMD.. 2008 Jul 0; 10(4):338-45. Epub 2008 Jun 13.

Mulford D. "Antibody therapy for acute myeloid leukemia." Seminars in hematology.. 2008 Apr 0; 45(2):104-9.

Mulford DA, Scheinberg DA, Jurcic JG. "The promise of targeted {alpha}-particle therapy." Journal of nuclear medicine : official publication, Society of Nuclear Medicine.. 2005 Jan 0; 46 Suppl 1:199S-204S.

Mulford DA, Jurcic JG. "Antibody-based treatment of acute myeloid leukaemia." Expert opinion on biological therapy.. 2004 Jan 0; 4(1):95-105.

Mulford, D.; Pandit-Taskar, N.; McDevitt, M.; Finn, R.; Weiss, M.; Apostolidis, C.; Morgenstern, A.; Divgi, C.; Larson, S.; Scheinberg, D., Jurcic, J.;. "Sequential therapy with cytarabine and bismuth-213 (213Bi)-labeled-HuM195 (anti-CD33) for acute myeloid leukemia (AML)". Blood. 2004; .

Mulford, D.; Divgi, C.; McDevitt, M.; Sgouros, G.; Finn, R.; Larson, S.; Apostolidis, C.; Morgenstern, A.; Scheinberg, D.; Jurcic, J.;. "Bismuth-labeled anti-CD33 antibody for elimination of minimal residual disease in acute myeloid leukemia". 10th Conference on Cancer Therapy with Antibodies & Immunoconjugates. 2004; .

Mulford, D.; Maslak, P.; Weiss, M.; Scheinberg, D.; Jurcic, J.;. "Reducing standard postremission chemotherapy in acute promyelocytic leukemia (APL) with risk-adapted therapy." Blood. 2003; : 619a.

Landau, H.; Mulford, D.; Jurcic, J.; Lammanna, N.; Weiss, M.;. "Retrospective study to determine if the presence of trisomy 12 by FISH and cytogenetics is predictive of a slowly-progressive chronic lymphocytic leukemia." `. .

Books & Chapters

Chapter Title: Monoclonal Antibody Therapies of Cancer
Book Title: Cancer Chemotherapy and Biotheraphy
Author List: Scheinberg DA, Mulford DA, Jurcic JG, Junghans RP, Sgouros G.
Published By: Baltimore: Lippincott, Williams, And Wilkins2006